{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/hybrid-protocol-accelerated-success#webpage",
"url": "https://www.fortrea.com/insights/hybrid-protocol-accelerated-success",
"name": "Hybrid protocol: Accelerated success",
"description": "This Fortrea case study explores how a hybrid protocol design supported accelerated success in first in human clinical trials for an immunology drug development program. The study combined healthy volunteer cohorts with patient cohorts within a single adaptive protocol, enabling earlier assessment of safety, tolerability, pharmacokinetics, and preliminary efficacy data. By implementing adaptive trial strategies and streamlined protocol development, the approach supported faster go/no-go decision-making while reducing the time and cost associated with separate studies. The case study highlights how hybrid protocol design, integrated clinical pharmacology expertise, and adaptive operational execution improved trial efficiency and strengthened early clinical development for the biotech sponsor. This case study demonstrates how innovative first in human clinical trial strategies can accelerate decision-making and support more efficient immunology drug development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hybrid protocol: Accelerated success",
"item": "https://www.fortrea.com/insights/hybrid-protocol-accelerated-success"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/hybrid-protocol-accelerated-success#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/hybrid-protocol-accelerated-success#webpage"
},
"headline": "Hybrid Protocol Design for First in Human Clinical Trials | Fortrea Case Study",
"description": "This Fortrea case study explores how a hybrid protocol design supported accelerated success in first in human clinical trials for an immunology drug development program. The study combined healthy volunteer cohorts with patient cohorts within a single adaptive protocol, enabling earlier assessment of safety, tolerability, pharmacokinetics, and preliminary efficacy data. By implementing adaptive trial strategies and streamlined protocol development, the approach supported faster go/no-go decision-making while reducing the time and cost associated with separate studies. The case study highlights how hybrid protocol design, integrated clinical pharmacology expertise, and adaptive operational execution improved trial efficiency and strengthened early clinical development for the biotech sponsor. This case study demonstrates how innovative first in human clinical trial strategies can accelerate decision-making and support more efficient immunology drug development programs.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-03/hybrid-protocol-accelerated-success.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-17",
"dateModified": "2025-03-17",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/hybrid-protocol-accelerated-success.pdf",
"encodingFormat": "application/pdf"
}
}
]
}